Ayala Pharmaceuticals Inc (ADXS)

[The_Pro]

Zacks just released their report on yesterday's 3 presentations:

http://finance.yahoo.com/news/adxs-advaxis-three-presentations-2015-142200503.html


We Raise Our Price Target to $25

We maintain our Outperform rating for ADXS and raise our 12-month price target to $30.00 per share from previous $18.00 per share based on the recent clinical achievements.

Some encouragement. ADXS could be first with a animal approval this year, 2015.



The recent deals are especially encouraging in our view. The deal with Aratana could get ADXS-cHER2 the first approved immunotherapy for animals in 2015. The deals with Biocon and GBP expand the usage of ADXS-HPV therapy for cervical cancer in the world two largest markets of cervical cancer in terms of patient population. The favorable terms in the deals not only strengthen Advaxis’ balance sheet in a non-dilutive way, but also validate the Company’s technology and clinical programs.

The collaborations with Merck and MedImmune may lead to license deals.

We look forward to the announcement of initiation of the pivotal Phase III trials of ADXS-HPV for recurring cervical cancer in 2015...............





This is my third post of the day. I will not be able to respond.



See ya

Sent from Yahoo Mail on Android